GT Biopharma Inc (GTBP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GT Biopharma Inc (GTBP) has a cash flow conversion efficiency ratio of -0.326x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.47 Million) by net assets ($7.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GT Biopharma Inc (GTBP) market capitalisation for the company's overall valuation and market capitalisation.
GT Biopharma Inc - Cash Flow Conversion Efficiency Trend (1985–2025)
This chart illustrates how GT Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
GT Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GT Biopharma Inc ranked by their cash flow conversion efficiency. Explore GTBP cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Investsmart Group Ltd
AU:INV
|
0.282x |
|
Standard Industries Limited
NSE:SIL
|
0.540x |
|
Origin Agritech Ltd
NASDAQ:SEED
|
0.012x |
|
Asuransi Dayin Mitra Tbk
JK:ASDM
|
-0.007x |
|
Saray Matbaacilik Kagitcilik Kirtasiyecilik Ticaret ve Sanayi AS
IS:SAMAT
|
-0.082x |
|
Adagio Medical Holdings, Inc Common Stock
NASDAQ:ADGM
|
12.675x |
|
Tan Dai Hung Plastic JSC
VN:TPC
|
N/A |
|
PATERSON RESOURCES LTD
F:U40
|
N/A |
Annual Cash Flow Conversion Efficiency for GT Biopharma Inc (1985–2025)
The table below shows the annual cash flow conversion efficiency of GT Biopharma Inc from 1985 to 2025. View GTBP stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.79 Million | $-12.91 Million | -2.232x | -128.88% |
| 2024-12-31 | $-1.67 Million | $-12.90 Million | 7.727x | +752.58% |
| 2023-12-31 | $7.48 Million | $-8.85 Million | -1.184x | +8.70% |
| 2022-12-31 | $11.73 Million | $-15.22 Million | -1.297x | -82.07% |
| 2021-12-31 | $21.91 Million | $-15.61 Million | -0.712x | -388.69% |
| 2020-12-31 | $-29.43 Million | $-7.26 Million | 0.247x | +30.21% |
| 2019-12-31 | $-19.31 Million | $-3.66 Million | 0.189x | +120.18% |
| 2018-12-31 | $11.37 Million | $-10.68 Million | -0.939x | -4252.64% |
| 2017-12-31 | $251.69 Million | $-5.43 Million | -0.022x | -121.15% |
| 2016-12-31 | $-18.92 Million | $-1.93 Million | 0.102x | +10.74% |
| 2015-12-31 | $-50.57 Million | $-4.66 Million | 0.092x | +55.72% |
| 2014-12-31 | $-29.57 Million | $-1.75 Million | 0.059x | -15.25% |
| 2013-12-31 | $-6.33 Million | $-442.00K | 0.070x | -55.20% |
| 2012-12-31 | $-6.34 Million | $-987.00K | 0.156x | -17.49% |
| 2011-12-31 | $-5.10 Million | $-963.00K | 0.189x | -32.74% |
| 2010-12-31 | $-5.47 Million | $-1.53 Million | 0.281x | +71.46% |
| 2009-12-31 | $-5.72 Million | $-937.00K | 0.164x | +256.45% |
| 2008-12-31 | $-3.68 Million | $-169.00K | 0.046x | +127.71% |
| 2007-12-31 | $1.63 Million | $-270.00K | -0.166x | +95.18% |
| 2006-12-31 | $195.00K | $-671.00K | -3.441x | -481.67% |
| 2005-12-31 | $3.54 Million | $-2.09 Million | -0.592x | -229.06% |
| 2004-12-31 | $5.80 Million | $-1.04 Million | -0.180x | +31.70% |
| 2003-12-31 | $870.00K | $-229.00K | -0.263x | +68.19% |
| 2002-12-31 | $1.22 Million | $-1.01 Million | -0.828x | +69.05% |
| 2001-12-31 | $533.00K | $-1.43 Million | -2.674x | -180.15% |
| 2000-12-31 | $4.07 Million | $-3.89 Million | -0.954x | -3.60% |
| 1999-12-31 | $2.69 Million | $-2.48 Million | -0.921x | -27.55% |
| 1998-12-31 | $7.20 Million | $-5.20 Million | -0.722x | -2.31% |
| 1997-12-31 | $6.80 Million | $-4.80 Million | -0.706x | +26.13% |
| 1996-12-31 | $4.50 Million | $-4.30 Million | -0.956x | +22.47% |
| 1995-12-31 | $4.30 Million | $-5.30 Million | -1.233x | -2164.53% |
| 1994-12-31 | $6.70 Million | $400.00K | 0.060x | +110.45% |
| 1993-12-31 | $2.80 Million | $-1.60 Million | -0.571x | -391.43% |
| 1992-12-31 | $4.30 Million | $-500.00K | -0.116x | -167.44% |
| 1991-12-31 | $4.60 Million | $-200.00K | -0.043x | -123.19% |
| 1990-12-31 | $4.80 Million | $900.00K | 0.188x | +4.46% |
| 1989-12-31 | $3.90 Million | $700.00K | 0.179x | +474.36% |
| 1988-12-31 | $3.20 Million | $100.00K | 0.031x | +93.75% |
| 1987-12-31 | $3.10 Million | $50.00K | 0.016x | +111.29% |
| 1986-12-31 | $2.80 Million | $-400.00K | -0.143x | -47.62% |
| 1985-12-31 | $3.10 Million | $-300.00K | -0.097x | -- |
About GT Biopharma Inc
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, tha… Read more